pivotal

AstraZeneca faces a significant setback as the breast cancer drug camizestrant fails to meet primary endpoints in a pivotal first-line clinical trial.

The pharmaceutical giant AstraZeneca confirmed on Friday that its novel oral endocrine therapy, camizestrant, failed to demonstrate a superior clinical…